Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:BNR NASDAQ:LFMD NASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$14.25+0.6%$14.52$5.00▼$20.21$143.24M0.4385,325 shs29,666 shsBNRBurning Rock Biotech$16.93-0.7%$18.44$2.49▼$41.72$179.23M1.4922,213 shs5,004 shsLFMDLifeMD$4.24-2.1%$4.09$2.56▼$15.84$209.41M2.031.28 million shs847,215 shsSERASera Prognostics$1.75+1.7%$1.99$1.37▼$4.09$67.35M0.9242,718 shs31,577 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+0.56%-11.55%+8.45%+11.50%+136.55%BNRBurning Rock Biotech-0.65%+4.44%-18.10%-42.71%+494.00%LFMDLifeMD-2.08%-3.42%+3.67%+48.77%-60.45%SERASera Prognostics+1.74%+1.16%-23.91%-32.43%-24.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$14.25+0.6%$14.52$5.00▼$20.21$143.24M0.4385,325 shs29,666 shsBNRBurning Rock Biotech$16.93-0.7%$18.44$2.49▼$41.72$179.23M1.4922,213 shs5,004 shsLFMDLifeMD$4.24-2.1%$4.09$2.56▼$15.84$209.41M2.031.28 million shs847,215 shsSERASera Prognostics$1.75+1.7%$1.99$1.37▼$4.09$67.35M0.9242,718 shs31,577 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+0.56%-11.55%+8.45%+11.50%+136.55%BNRBurning Rock Biotech-0.65%+4.44%-18.10%-42.71%+494.00%LFMDLifeMD-2.08%-3.42%+3.67%+48.77%-60.45%SERASera Prognostics+1.74%+1.16%-23.91%-32.43%-24.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.50Moderate Buy$31.00117.54% UpsideBNRBurning Rock Biotech 1.00SellN/AN/ALFMDLifeMD 2.67Moderate Buy$9.14115.63% UpsideSERASera Prognostics 2.50Moderate Buy$5.00185.71% UpsideCurrent Analyst Ratings BreakdownLatest SERA, LFMD, BNR, and BDSX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026LFMDLifeMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D)5/5/2026BDSXBiodesix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $22.005/4/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/4/2026LFMDLifeMD BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/20/2026BNRBurning Rock Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026LFMDLifeMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026SERASera Prognostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026LFMDLifeMD MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$6.00 ➝ $8.003/12/2026LFMDLifeMD Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.003/11/2026LFMDLifeMD HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.003/10/2026LFMDLifeMD Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$88.50M1.63N/AN/A($0.31) per share-45.97BNRBurning Rock Biotech$77.16M2.31N/AN/A$7.28 per share2.33LFMDLifeMD$194.05M1.06N/AN/A$0.48 per share8.83SERASera Prognostics$57K1,202.25N/AN/A$1.94 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/6/2026 (Estimated)BNRBurning Rock Biotech-$7.92M-$0.79N/AN/AN/A-10.27%-9.98%-6.69%6/2/2026 (Estimated)LFMDLifeMD$14.35M$0.0584.8211.46N/A2.37%-150.88%-22.59%8/5/2026 (Estimated)SERASera Prognostics-$31.93M-$0.65N/AN/AN/A-56,385.97%-41.02%-30.95%8/5/2026 (Estimated)Latest SERA, LFMD, BNR, and BDSX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2026Q1 2026BNRBurning Rock Biotech-$2.2884N/AN/AN/A$19.21 millionN/A5/6/2026Q1 2026LFMDLifeMD-$0.14-$0.20-$0.06-$0.20$48.84 million$50.16 million5/6/2026Q1 2026SERASera Prognostics-$0.16-$0.17-$0.01-$0.17$0.07 million$0.01 million5/4/2026Q1 2026BDSXBiodesix-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million3/18/2026Q4 2025SERASera Prognostics-$0.17-$0.16+$0.01-$0.16$0.03 million$0.01 million3/13/2026Q4 2025BNRBurning Rock BiotechN/A-$0.21N/A-$0.21N/A$18.05 million3/9/2026Q4 2025LFMDLifeMD-$0.01-$0.04-$0.03$0.41$48.57 million$46.87 million2/26/2026Q4 2025BDSXBiodesix-$1.05-$0.49+$0.56-$0.49$26.25 million$28.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/ABNRBurning Rock BiotechN/AN/AN/AN/AN/ALFMDLifeMDN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix5.092.822.82BNRBurning Rock BiotechN/A2.992.79LFMDLifeMDN/A1.040.98SERASera PrognosticsN/A2.122.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%BNRBurning Rock Biotech30.03%LFMDLifeMD35.52%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix23.20%BNRBurning Rock Biotech30.30%LFMDLifeMD18.40%SERASera Prognostics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix22010.11 million7.76 millionNo DataBNRBurning Rock Biotech1,39010.52 million7.33 millionNot OptionableLFMDLifeMD23048.36 million39.46 millionOptionableSERASera Prognostics12039.16 million34.73 millionOptionableSERA, LFMD, BNR, and BDSX HeadlinesRecent News About These CompaniesSera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 14, 2026 | zacks.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2026 Financial ResultsMay 9, 2026 | finanznachrichten.deWill Sera Prognostics (NASDAQ:SERA) Spend Its Cash Wisely?May 8, 2026 | finance.yahoo.comSera Prognostics Balances Cash Strength With Slow RampMay 7, 2026 | tipranks.comSera Prognostics, Inc. (SERA) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comSera Prognostics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comSera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPSMay 6, 2026 | marketbeat.comSera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue EstimatesMay 6, 2026 | zacks.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTSMay 6, 2026 | prnewswire.comSera Prognostics (SERA) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comSERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026April 22, 2026 | prnewswire.comSera Prognostics Inc.April 11, 2026 | barrons.comSera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?March 31, 2026 | zacks.com5 Top-Ranked Stocks With Rising P/E That Investors Can Bet OnMarch 31, 2026 | zacks.comSera Prognostics, Inc. (NASDAQ:SERA) Q4 2025 earnings call transcriptMarch 20, 2026 | msn.comSera Prognostics Earnings Call: Data-Rich, Revenue-LightMarch 19, 2026 | tipranks.comSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial ResultsMarch 19, 2026 | finanznachrichten.deSera Prognostics Inc (SERA) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges and ...March 19, 2026 | uk.finance.yahoo.comSera Prognostics Sets Stage for Commercial Success with Strong 2025 PerformanceMarch 19, 2026 | news.themarketisopen.comNSera Prognostics outlines plan to expand partner programs to 15–17 states by year-end 2026 while maintaining cash runway through 2028March 19, 2026 | seekingalpha.comSera Prognostics Q4 2025 Earnings Call TranscriptMarch 19, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSERA, LFMD, BNR, and BDSX Company DescriptionsBiodesix NASDAQ:BDSX$14.25 +0.08 (+0.56%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$14.21 -0.04 (-0.28%) As of 05:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Burning Rock Biotech NASDAQ:BNR$16.93 -0.11 (-0.65%) Closing price 05/18/2026 03:58 PM EasternExtended Trading$16.93 +0.00 (+0.01%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.LifeMD NASDAQ:LFMD$4.24 -0.09 (-2.08%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$4.18 -0.06 (-1.42%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.Sera Prognostics NASDAQ:SERA$1.75 +0.03 (+1.74%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$1.78 +0.03 (+2.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
